Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) EPS (Weighted Average and Diluted): 2022-2024

Historic EPS (Weighted Average and Diluted) for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to -$1.02.

  • Day One Biopharmaceuticals' EPS (Weighted Average and Diluted) fell 150.00% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.52, marking a year-over-year decrease of 47.57%. This contributed to the annual value of -$1.02 for FY2024, which is 56.96% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.02, which was up 56.96% from -$2.37 recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of -$1.02 in FY2024 and a low of -$2.37 during FY2023.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$1.85, with a median of -$2.17 in 2022.
  • In the last 5 years, Day One Biopharmaceuticals' EPS (Weighted Average and Diluted) decreased by 9.22% in 2023 and then spiked by 56.96% in 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.17 in 2022, then decreased by 9.22% to -$2.37 in 2023, then spiked by 56.96% to -$1.02 in 2024.